Because the price has almost nothing to do with the manufacturing. A 2026 analysis in Obesity estimates that generic injectable semaglutide could be produced and sold for $28 to $140 per person-year [1]. The cheapest injectable semaglutide figure among 404 sellers tracked here works out to $912 across a year, roughly 6 times the top of that range.
That comparison is worth making carefully, because the two numbers are not the same kind of thing. Treating them as one would mislead anyone using this desk to judge whether a seller is charging fairly. The full spread of what sellers publish is set out in what a GLP-1 actually costs, and the modeled floor belongs underneath all of it rather than beside any one row.
What the $28 to $140 is
The researchers built their estimate by cost-plus modeling, taking active ingredient shipment data out of India for 2024 and 2025 and adding assumptions for formulation, packaging, taxation and a profit margin. What comes out is an estimate of what it would cost a manufacturer to produce and sell the drug, which is a floor beneath a price rather than a price anybody has been quoted.
The distance between that floor and what a reader actually pays is not one company’s markup. It covers the patent that funded the original trials, the injection device, the pharmacy that fills the order and the clinician who writes it, alongside whatever margin the seller takes. Most of what this desk ranks is compounded or cash-pay telehealth semaglutide rather than the licensed generic the paper models. So the gap is a scale check and not a like-for-like comparison. Whether a published figure is the figure you are billed is handled separately in the headline against the bill.
The device is not the expensive part
One finding lands directly on a question this desk has measured from the other end. The authors report that injection devices contribute disproportionately to the total modeled cost, and their estimate for an oral formulation runs $186 to $380 per person-year, well above the injectable range. Sellers here price the two formats the same direction. Comparing sellers against themselves rather than against each other shows the tablet usually costs more. That is the rarer case of a modeling paper and a price sweep agreeing without either having consulted the other.
What the price does to who gets it
Seven years of national survey data show what a high price looks like from the demand side [2]. Use rose roughly tenfold, from 0.42% to 4.45% of adults, while spending per prescription rose by nearly half. Against privately insured, higher-income, college-educated white adults as the reference, uninsured adults had 0.53 times the odds of use (95% CI 0.31–0.92).
The same analysis contradicts the usual story about who is taking these drugs. Prescribing outside an approved indication fell from 27% to 12% across the period, so the share of use that was off-label more than halved while total use rose tenfold. A high price filters by income, not by need.
The budget side shows the same premium from above. In Croatia, GLP-1 drugs reached 16.1% of non-insulin diabetes prescriptions and 42.7% of the category’s spending by 2024, or €42.07 million in one year [3]. That gap between a sixth of the scripts and two fifths of the money is what a premium drug looks like on a budget line.
The price is also the input that decides value
Cost-effectiveness models do not measure the price, they assume it. One model reached $19,911 per quality-adjusted life year for semaglutide 2.4 mg [4], and the list price it used does more work in that result than any clinical assumption in the model. Change the price input and the conclusion changes with it, which is why the authorship of a model matters.
Where the price can go
The geography in the production paper is the part with policy behind it. Twelve countries whose patents expire in 2026 account for 47% of global obesity and 49% of type 2 diabetes. No patent filings were identified in a further 150 countries. The authors calculate that by the end of 2026, generic injectable semaglutide could become available in 162 countries representing 69% of global type 2 diabetes and 84% of clinical obesity. The paper does not name the twelve countries, so neither will this article.
For anyone buying today the practical reading is narrow but real. A market whose production floor sits this far below its prices is a market where prices have room to move. That is an argument for keeping the ability to move with them, and against signing away a year to capture a discount. The arithmetic is worked through in what a twelve-month commitment locks you out of. Desk figures in this article were read from the 404 sellers publishing an injectable semaglutide price as of September 2026.